Aclaris Therapeutics, Inc. reported a net loss of $45.1 million for the nine months ended September 30, 2025, compared to a net loss of $35.5 million for the same period in 2024. Total revenue for the nine-month period decreased to $6.5 million from $9.5 million year-over-year, primarily due to declines in both contract research and licensing revenues. Contract research revenue fell to $1.4 million from $1.9 million, while licensing revenue decreased to $5.2 million from $7.6 million, attributed to fewer milestone achievements under existing agreements.
The company’s total expenses for the nine months ended September 30, 2025, increased to $60.2 million from $51.8 million in the prior year. This rise was driven by a significant increase in research and development costs, which surged to $36.1 million from $24.6 million, reflecting ongoing investments in clinical trials and product development. General and administrative expenses also saw a slight decrease, totaling $16.4 million compared to $17.2 million in the previous year.
Aclaris has made strategic advancements, including the initiation of a Phase 2 trial for its investigational drug bosakitug, aimed at treating moderate to severe atopic dermatitis. The company also entered into an exclusive license agreement with Biosion, granting rights to develop and commercialize bosakitug and ATI-052, which is expected to enhance its product pipeline. As of September 30, 2025, Aclaris had cash, cash equivalents, and marketable securities totaling $167.2 million, down from $220.3 million at the end of 2024, indicating a need for continued capital to support its operations and development efforts.
Operationally, Aclaris has seen fluctuations in its workforce, having reduced its employee count by approximately 46% in late 2023, which has impacted its operational costs. The company reported a total of 108.3 million shares outstanding as of October 31, 2025, reflecting its ongoing efforts to manage equity and capital structure. Looking ahead, Aclaris anticipates continued net losses as it advances its product candidates through clinical development, with a focus on securing additional funding and strategic partnerships to support its long-term business objectives.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel small and large molecule therapies for immuno-inflammatory diseases. Utilizing its proprietary KINect drug discovery platform, Aclaris advances biologics and kinase inhibitor candidates targeting validated pathways. Its pipeline includes monoclonal and bispecific antibodies, oral kinase inhibitors, and topical treatments. The company serves patients with unmet medical needs through research, development, and strategic partnerships, relying on third-party manufacturing and regulatory approvals.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.